Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$2.93 - $3.96 $55 - $75
-19 Reduced 0.18%
10,609 $31,000
Q2 2022

Aug 15, 2022

BUY
$2.74 - $13.43 $1,260 - $6,177
460 Added 4.52%
10,628 $32,000
Q1 2022

May 16, 2022

BUY
$8.96 - $13.51 $91,105 - $137,369
10,168 New
10,168 $138,000
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $109,480 - $195,680
-11,939 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $109,241 - $132,403
11,939 New
11,939 $112,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $18.9M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.